Skip to main content
Clinical Trials/NCT02302612
NCT02302612
Completed
Not Applicable

Multi-Component Behavioral Intervention for Complex Patients With CVD Risk. The Changing Results: Engage and Activate to Enhance Wellness (CREATE Wellness) Study

Kaiser Permanente1 site in 1 country647 target enrollmentJanuary 2015

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Diabetes
Sponsor
Kaiser Permanente
Enrollment
647
Locations
1
Primary Endpoint
Composite CVD Goal
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

Cardiovascular disease (CVD) is the leading cause of death in the U.S. Efforts to improve CVD risk factors often fall short in complex patients with multiple co-morbid conditions, a growing, expensive, and high-risk segment of the U.S. population. The investigators are testing a multi-component behavioral intervention designed to help complex patients with CVD and other concurrent chronic conditions to become more effective agents of their own care.

Detailed Description

Cardiovascular disease (CVD) is the leading cause of death in the U.S. Despite the availability of evidence-based guidelines and efficacious therapies, however, many patients do not achieve the full benefit of CVD risk reduction. In particular, complex patients (defined as those patients who do not respond to current disease management approaches) with multiple concurrent chronic conditions represent a key segment of the population that would benefit from new approaches to care. In response to PA-12-024: Behavioral Interventions to Address Multiple Chronic Conditions in Primary Care, which seeks "practical interventions...to modify behaviors using a common approach" among patients with multiple co-morbidities, the investigators are testing an integrated behavioral intervention designed to improve a core set of chronic disease self-management skills and to overcome common barriers to care engagement encountered by this increasingly important segment of the U.S. adult primary care population. This randomized trial will be conducted within Kaiser Permanente Northern California (KPNC), an integrated care delivery system serving over 3.2 million members, including patients insured through Medicare and state Medicaid programs. The investigators will evaluate the intervention in 3 KPNC primary care practices by enrolling 576 complex patients who have persistently (≥ 2 years) uncontrolled CVD risk factors (e.g. hypertension, hyperlipidemia, diabetes) despite being enrolled in a CVD disease management program. This behavioral intervention is designed to activate and engage patients, identify potentially hidden barriers to care such as alcohol misuse or sub-clinical depression, and to develop individualized care plans that are designed to catalyze more effective primary care management. Randomization will be at the patient-level. The investigators will examine the impact of the intervention on clinical outcomes (control of systolic blood pressure, HbA1c (if with diabetes), statin treatment rates) after 12 months and patient-reported outcomes (patient activation, medication adherence, and mental health status) after 6 months. By focusing on core health skills and care barriers, this patient-focused intervention seeks to enable complex patients to become more effective agents of their own care and to thereby achieve similar clinical benefits as less complex patients.

Registry
clinicaltrials.gov
Start Date
January 2015
End Date
September 30, 2018
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Kaiser Permanente Northern California members enrolled in the PHASE disease management program and not meeting all goals of care for the preceding 2 years.

Exclusion Criteria

  • Schizophrenia or personality disorder
  • Unable to communicate in English
  • Unwilling to participate in group-based in-person program
  • Terminal or debilitating illness

Outcomes

Primary Outcomes

Composite CVD Goal

Time Frame: 12-months

We will compare the proportion of patients in the two study arms who achieve all three clinical goals of the PHASE disease management program (blood pressure control, HbA1c control (if applicable), and statin prescription) 12 months after enrollment. Risk factor control is defined according to the PHASE disease management program protocol.

Secondary Outcomes

  • Effective Consumer Scale (EC-17)(6 months)
  • Perceived efficacy in patient-physician interactions (PEPPI) - 10 items(6 months)
  • Patient Activation Measure (PAM) - 13 items(6 months)

Study Sites (1)

Loading locations...

Similar Trials